Perampanel in the treatment of patients with epilepsy

Rider F.K.

doi:https://doi.org/10.17116/jnevro20171179263-69

Close metadata

Recommended articles:

Personality profile caused by epilepsy according to the «Big Five» model. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):16-21

Brain microstructural abnormalities assessed by diffusion kurtosis MRI in patients with focal temporal lobe epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):171-177

Ototoxicity caused by anti-epileptic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):14-19

Absence status epilepticus in adults. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):47-56

Open observational study with a retrospective analysis of the efficacy and tolerability of aceclofenac in patients with acute non-specific low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):99-105

Comorbid anxiety disorders in patients with neurological pathology: current state of the problem and the role of etifoxine in treatment strategy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):126-136

On the issue of choosing anesthesia methods: a comparison of general medicine and clinical dentistry. Stomatology. 2025;(1):76-80

Autonomic cardiovascular disorders in patients with epileptic and psychogenic non-epileptic seizures: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):13-20

Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68

Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):69-79

Abstract:

Development of new antiepileptic drugs (AED) does not stop due to the fact that the number of patients with pharmacoresistant epilepsy remains at about 30%. One of the newest AEDs is perampanel (PER), a selective, non-competitive AMPA receptor antagonist to target post-synaptic glutamate transmission. PER is approved in the Russian Federation as adjunctive treatment for focal seizures with or without secondarily generalized seizures and for primary generalized tonic-clonic (PGTC) seizures in idiopathic generalized epilepsy (IGE) in patients with epilepsy aged ≥12 years. The drug is effective and well-tolerated in the dose of 4—8 mg/day, and most side effects are dose-dependent. The high efficacy of PER combined with the good tolerability, absence of life-threatening adverse reactions and convenient intake allow us to recommend PER as the first choice additional drug in treatment of patients with epilepsy.

Keywords:

epilepsy

antiepileptic drugs

perampanel

efficacy

tolerability

Authors:

Rider F.K.

Soloviev Moscow Research and Clinical for Neuropsychiatry, Moscow, Russia

Close metadata

References:

Brigo F, Bragazzi NL, Nardone R, Trinka E. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: results of an indirect comparison meta-analysis of RCTs. Seizure. 2016;42:29-37. https://doi.org/10.1016/j.seizure.2016.08.007
Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548-1554. https://doi.org/10.1212/wnl.0b013e3182563b19
Davydova ON, Boldyrev AA. Glutamate receptors in cells of the nervous and immune systems. Annaly klinicheskoi i eksperimental’noi nevrologii. 2007;4:28-34. (In Russ.)
Rogawski MA. AMPA receptors as a molecular a molecular target in epilepsy therapy. Acta Neurol Scand. 2013;127(suppl 197):9-18. https://doi.org/10.1111/ane.12099
Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007;4:18-61. https://doi.org/10.1016/j.nurt.2006.11.010
Barygin OI. Inhibition of calcium-permeable and calcium-impermeable AMPA receptors by perampanel in rat brain neurons. Neurosci Lett. 2016;633:146-151. https://doi.org/10.1016/j.neulet.2016.09.028
Barygin OI, Komarova MS, Tikhonova TB, Tikhonov DB. Non-classical mechanism of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor channel block by fluoxetine. Eur J Neurosci. 2015;41(7):869-877. https://doi.org/10.1111/ejn.12817
Khodorov B. Glutamate-induced deregulation of calcium homeostasis and mitochondrial dysfunction in mammalian central neurones. Prog Biophys Mol Biol. 2004;86(2):279-351. https://doi.org/10.1016/j.pbiomolbio.2003.10.002
Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12-27. https://doi.org/10.1111/epi.12865
Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52:1331-1340. https://doi.org/10.1111/j.1528-1167.2011.03109.x
Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int. 2012;61:517-522. https://doi.org/10.1016/j.neuint.2012.02.035
Wu T, Nagaya Y, Hanada T. Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model. Seizure. 2014;23(9):732-739. https://doi.org/10.1016/j.seizure.2014.06.001
Zwart R, Sher E, Ping X, Jin X, Sims JR Jr, Chappell AS, Gleason SD, Hahn PJ, Gardinier K, Gernert DL, Hobbs J, Smith JL, Valli SN, Witkin JM. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models. J Pharmacol Exp Ther. 2014t;351(1):124-133. https://doi.org/10.1124/jpet.114.212779
Belousova ED. Efficacy and tolerability of perampanel as additional drug of teenagers with drugresistant partial epilepsy: results of a randomized doubleblind placebocontrolled study conducted in the Russian Federation. Epilepsiya i paroksizmal’nye sostoyaniya. 2014;(1):27-33. (In Russ.)
Vlasov PN. Efficacy and tolerability:results of a double-blind, placebo-controlled, and extended open study evaluating the long-term safety and efficacy perampanela in Russia. Epilepsiya i paroksizmal’nye sostoyaniya. 2014;(1):16-17. (In Russ.)
Karlov VA, Belyaev OV, Vlasov PN, Zhidkova IA, Volkov IV, Dmitrenko DV, Karas AYu, Kazennykh TV, Miguskina OI, Moskvicheva AV, Paramonova EN, Ponomareva IV, Chervyakov AV. Russian experience with perampanel in routine clinical practice. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2016;(spetsvypusk 1):11-17. (In Russ.)
US Food and Drug Administration FDA. Clinical pharmacology review. Reference ID: 3205587 2012. The link is active on: 23.08.17. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM332052.pdf
Laurenza A, Ferry J, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Poster presented at the 65th American Epilepsy Society (AES) Annual Meeting, Baltimore, MD, USA; December 2—6, 2011. Poster number P2.231.
Schulze-Bonhage A. Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation. Expert Opin Drug Metab Toxicol. 2015;11(8):1329-1337. https://doi.org/10.1517/17425255.2015.1061504
European Medicines Agency EMA, Fycompa SPC. Perampanel (Fycompa). Summary of product characteristics. Updated 13 November 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/ WC500130815.pdf
Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clément J-F, Wang X, Bagul M, Gee M, Zhu J, Squillacote D. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307. Epilepsia. 2014;55(7):1058-1068. https://doi.org/10.1111/epi.12643
Pylaeva OA, Mukhin KYu. Use of the new antiepileptic drug perampanel (Fycompa) in the treatment of epilepsy: a review of foreign literature. Russkii zhurnal detskoi nevrologii. 2014;3:36-42. (In Russ.)
Villanueva V, Garcés M, López-González FJ, Rodriguez-Osorio X, Toledo M, Salas-Puig J, González-Cuevas M, Campos D, Serratosa JM, González-Giráldez B, Mauri JA, Camacho JL, Suller A, Carreño M, Gómez JB, Montoya J, Rodríguez-Uranga J, Saiz-Diaz R, González-de la Aleja J, Castillo A, López-Trigo J, Poza JJ, Flores J, Querol R, Ojeda J, Giner P, Molins A, Esteve P, Baigesr JJ. Erratum to «Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study». Epilepsy Res. 2017;129:174-175. https://doi.org/10.1016/j.eplepsyres.2016.12.005
Juhl S, Rubboli G. Perampanel as add-on treatment in refractory focal epilepsy. The Dianalund experience. Acta Neurol Scand. 2016;134(5):374-377. https://doi.org/10.1111/ane.12558
Mkrtchyan VR, Sergeev AM, Pochigaeva KI, Shpak IA. Budget impact analysis of perampanel for adjunctive treatment in epilepsy patients 12 years of age and older for partial onset seizures with or without secondary generalization and primary generalized tonic-clonic seizures in the Russian Federation. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2016;2:28-37. (In Russ.)
French JA., Krauss GL, Wechsler RT, Wang X, DiVentura B, Brandt C, Trinka E, O’Brien TJ, Laurenza A, Patten A, Bibbiani F. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. A randomized trial. Neurology. 2015;85:1-8. https://doi.org/10.1212/wnl.0000000000001930
Auvin S, Dozieres B, Ilea A, Delanoë C. Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome. Epilepsy Behav. 2017;74:59-63. https://doi.org/10.1016/j.yebeh.2017.05.036
Steinhoff BJ, Bacher M, Bast T, Kornmeier R, Kurth C, Scholly J, Staack AM, Wisniewski I. First clinical experiences with perampanel — the Kork experience in 74 patients. Epilepsia. 2014;55(suppl 1):16-18. https://doi.org/10.1111/epi.12492
Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, Squillacote D, Yang H, Zhu J, Laurenza A. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54(8):1481-1489. https://doi.org/10.1111/epi.12212
Brodie MJ. Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy. CNS Drugs. 2015;29(11):893-904. https://doi.org/10.1007/s40263-015-0285-4
Ettinger AB, LoPresti A, Yang H, Williams B, Zhou S, Fain R, Laurenza A. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56(8):1252-1263. https://doi.org/10.1111/epi.13054
Rosenfeld W, Conry J, Lagae L, Rozentals G, Yang H, Fain R, Williams B, Kumar D, Zhu J, Laurenza A. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015;19(4):435-445. https://doi.org/10.1016/j.ejpn.2015.02.008
Trinka E, Steinhoff BJ, Nikanorova M, Brodie MJ. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurol Scand. 2016;133(3):160-172. https://doi.org/10.1111/ane.12529
Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S, Benedetto U. Tolerability of new antiepileptic drugs: a network meta-analysis. Eur J Clin Pharmacol. 2017;73(7):811-817. https://doi.org/10.1007/s00228-017-2245-z
Sirven JI, Fife TD, Wingerchuk DM, Drazkowski JF. Second-generation antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clin Proc. 2007;82(1):40-47. https://doi.org/10.4065/82.1.40.
Piedad J, Rickards H, Besag FM, Cavanna AE. Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations. CNS Drugs. 2012;26(4):319-335. https://doi.org/10.2165/11599780-000000000-00000
Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet. 2012;380(9848):1180-1192. https://doi.org/10.1016/s0140-6736(12)61455-x